Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead
11:11am, Wednesday, 14'th Aug 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has been awarded a 'Buy' rating from Jefferies analysts as the company's pipeline of mental health therapies enters a catalyst-rich period. “atai's pipeli
atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results
08:49am, Tuesday, 13'th Aug 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has provided an update on its research activities and told investors it has cash, marketable securities, and committed term loan funding available which is e
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
07:10am, Tuesday, 13'th Aug 2024
• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE'24 • Announced clinical development pla
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
12:12pm, Monday, 12'th Aug 2024
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stre
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
07:00am, Wednesday, 07'th Aug 2024
NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment o
atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know
01:02pm, Thursday, 11'th Jul 2024
atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Dirt-Cheap Drug Developers With Blockbuster Potential
07:00am, Thursday, 11'th Jul 2024
One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That's because the world of drug development and biotech
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
07:45am, Monday, 08'th Jul 2024
Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketam
3 Psychedelic Stocks to Ride to the Moon and Beyond
07:21am, Saturday, 06'th Jul 2024
The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
03:43pm, Tuesday, 02'nd Jul 2024
While the cannabis industry has all but become legitimate in the United States, it's not the only form of alternative medicine attempting to break through regulatory barriers. Compounds like psilocybi
atai Life Sciences CEO talks successful Phase 1 trial of IV psilocin formulation – ICYMI
10:34am, Saturday, 29'th Jun 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) recently welcomed encouraging results from Beckley Pystech's Phase 1 trial of its patient-protected intravenous (IV) formulation of psilocin ELE-101 in patien
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
07:00am, Wednesday, 26'th Jun 2024
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of
atai Life Sciences optimistic as IV psilocin shows promise in treating depression in early trial
08:42am, Thursday, 20'th Jun 2024
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has welcomed promising initial results from Beckley Psytech's Phase1 trial of its patient-protected intravenous (IV) formulation of psilocin ELE-101 in patien
NEW YORK and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of
atai Life Sciences poised for success with rigorous clinical trials
11:09am, Friday, 07'th Jun 2024
Analysts at Jefferies remain bullish on atai Life Sciences (NASDAQ:ATAI, ETR:9VC) as the broader psychedelic space this week hit a “technical setback.” On June 4, Lykos Therapeutics brought its a
